Target
triple kinase inhibitor
1 abstract
Abstract
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Moffitt Cancer Center, Tampa, FL,